Hirsutism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
*Effective measures for the secondary prevention of hirsutism include [[lifestyle]] modification and [[pharmacological]] prevention. | *Effective measures for the secondary prevention of hirsutism include [[lifestyle]] modification and [[pharmacological]] prevention. | ||
===Lifestyle modification=== | ===Lifestyle modification=== | ||
*First-line non-pharmacological therapy to decrease future [[cardiovascular]] and [[metabolic diseases]] ([[diabetes mellitus]]) | |||
*They have to be considered more in obese women with [[polycystic ovary syndrome|polycystic ovary syndrome (PCOS)]] | |||
*They are better to combine with: | |||
**[[Behavioral therapy|Behavioral therapies]] ([[psychological]]) | |||
**[[Diet]] | |||
**[[Exercise]]<ref name="pmid19463994">{{cite journal |vauthors=Karimzadeh MA, Javedani M |title=An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome |journal=Fertil. Steril. |volume=94 |issue=1 |pages=216–20 |year=2010 |pmid=19463994 |doi=10.1016/j.fertnstert.2009.02.078 |url=}}</ref><ref name="pmid23830153">{{cite journal |vauthors=Graff SK, Mário FM, Alves BC, Spritzer PM |title=Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes |journal=Fertil. Steril. |volume=100 |issue=4 |pages=1081–8 |year=2013 |pmid=23830153 |doi=10.1016/j.fertnstert.2013.06.005 |url=}}</ref><ref name="pmid18927072">{{cite journal |vauthors=Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ |title=Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis |journal=Hum. Reprod. Update |volume=15 |issue=1 |pages=57–68 |year=2009 |pmid=18927072 |doi=10.1093/humupd/dmn043 |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 19:35, 10 October 2017
|
Hirsutism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Hirsutism secondary prevention On the Web |
|
Directions to Hospitals Treating Hirsutism secondary prevention |
|
Risk calculators and risk factors for Hirsutism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rasam Hajiannasab M.D.[2] Eiman Ghaffarpasand, M.D. [3]
Overview
Effective measures for the secondary prevention of hirsutism include lifestyle modification and pharmacological prevention. The goal of secondary prevention is to prevent cardiovascular and metabolic diseases (diabetes mellitus).
Secondary Prevention
- Effective measures for the secondary prevention of hirsutism include lifestyle modification and pharmacological prevention.
Lifestyle modification
- First-line non-pharmacological therapy to decrease future cardiovascular and metabolic diseases (diabetes mellitus)
- They have to be considered more in obese women with polycystic ovary syndrome (PCOS)
- They are better to combine with:
References
- ↑ Karimzadeh MA, Javedani M (2010). "An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome". Fertil. Steril. 94 (1): 216–20. doi:10.1016/j.fertnstert.2009.02.078. PMID 19463994.
- ↑ Graff SK, Mário FM, Alves BC, Spritzer PM (2013). "Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes". Fertil. Steril. 100 (4): 1081–8. doi:10.1016/j.fertnstert.2013.06.005. PMID 23830153.
- ↑ Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ (2009). "Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis". Hum. Reprod. Update. 15 (1): 57–68. doi:10.1093/humupd/dmn043. PMID 18927072.